Fox Chase study: Melanoma peaks in middle‑aged mice
SkimNews Take
The immune system's age-related decline in specific cell types, rather than a universal weakening, creates distinct windows of vulnerability for cancer metastasis.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Fox Chase Cancer Center presented findings at the American Association for Cancer Research annual meeting showing that melanoma metastasis is lowest in young mice, peaks in middle‑aged mice, and declines again in very old mice.
- Gamma delta (γδ) T cells were found at higher levels in young and very old mice, where they keep melanoma dormant, while middle‑aged mice had fewer of these cells and more aggressive tumor spread.
- Melanoma cells in middle‑aged mice release molecules that suppress or exhaust γδ T cells, weakening immune defense and enabling dormant cancer cells to become metastatic.
- γδ T cells removal in young and very old mice increased melanoma spread significantly, while blocking the suppressive signals reduced metastasis.
- Mitchell Fane, PhD noted that most pre‑clinical cancer studies use young mice, which may explain why therapies that succeed in labs often fail in older human patients.
Why it matters: Pharma firms gain clearer paths to effective melanoma drugs for older adults, while patients avoid ineffective treatments; the study shows that age‑specific immune dynamics are essential for developing better therapies for older patients.
